title: [Renal enhancement and excretion of the hepatobiliary contrast agent Gd-EOB-DTPA].
abstract: OBJECTIVE
  To evaluate the clinical value of the renal clearance using MR imaging with different doses of gadolinium ethoxybenzyl-DTPA (Gd-EOB-DTPA) in comparison to gadolinium DTPA (Gd-DTPA).
  
  
  METHODS
  In a double-blind and randomized clinical phase II study. MR imaging at 1.5 T was performed in 61 patients with five different doses of Gd-EOB-DTPA (3, 6, 12.5, 25 and 50 micromol/kg b. w. as a bolus injection). The study protocol comprised T(1)- and T(2)-weighted spin-echo magnetic resonance and two-dimensional fast low-angle shot imaging before and at increasing intervals for up to 45 min after injection of Gd-EOB-DTPA. These images were compared with Gd-DTPA-enhanced imaging (0.1 mmol/kg b. w. as a bolus injection).
  
  
  RESULTS
  After bolus injection of the hepatobiliary MR contrast agent Gd-EOB-DTPA a renal elimination was observed. Immediately after the injection of Gd-EOB-DTPA until the eighth minute a corticomedullary enhancement of the kidney was conspicuous. After the fourth minute a contrast enhancement could be seen in the renal pelvis. The best enhancement was noted after 20 minutes in the FLASH GRE and T(1)-weighted images with good pelvicaliceal contrast. After 45 minutes an outflow of Gd-EOB-DTPA into the ureter could be observed.
  
  
  CONCLUSIONS
  In addition to the hepatobiliary secretion Gd-EOB-DTPA appears useful for the evaluation of renal structures and renal function on account of the renal excretion without diuretic preparation of the patients.
authors.affiliation: Institut für Diagnostische und Interventionelle Radiologie, Klinikum der Johann Wolfgang Goethe-Universität, Frankfurt/Main. Zangos@em.uni-frankfurt.de
authors.forename: S
authors.initials: S
authors.lastname: Zangos
authors.forename: R
authors.initials: R
authors.lastname: Hammerstingl
authors.forename: M G
authors.initials: MG
authors.lastname: Mack
authors.forename: R
authors.initials: R
authors.lastname: Straub
authors.forename: K
authors.initials: K
authors.lastname: Engelmann
authors.forename: K
authors.initials: K
authors.lastname: Eichler
authors.forename: T
authors.initials: T
authors.lastname: Balzer
authors.forename: T J
authors.initials: TJ
authors.lastname: Vogl
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D003287:Contrast Media / Q000008:administration & dosage / Q000493:pharmacokinetics; D005260:Female; D019786:Gadolinium DTPA / Q000008:administration & dosage / Q000493:pharmacokinetics*; D005704:Gallbladder / Q000378:metabolism; D006801:Humans; D007668:Kidney / Q000378:metabolism* / Q000502:physiology; D008099:Liver / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D051381:Rats; D013997:Time Factors; D014567:Urography / Q000379:methods*
chemical_list: D003287:Contrast Media; C073590:gadolinium ethoxybenzyl DTPA; D019786:Gadolinium DTPA